Exelixis Inc (NAS:EXEL)
$ 20.82 -0.41 (-1.93%) Market Cap: 6.06 Bil Enterprise Value: 5.44 Bil PE Ratio: 32.38 PB Ratio: 2.89 GF Score: 92/100

Exelixis Inc at Needham Healthcare Conference Transcript

Apr 10, 2019 / 08:10PM GMT
Release Date Price: $24.19 (+0.67%)
Chad Jason Messer
Needham & Company, LLC, Research Division - Senior Analyst

I think most of you know me, but I'm Chad Messer, Senior Biotech Analyst, here at Needham and with me today is Chris Senner, the Chief Financial Officer; and Andrew Peters, Vice President of Strategy from Exelixis. And I will kick it off so maybe one or both of you if you'd like to make some opening remarks.

Christopher J. Senner
Exelixis, Inc. - Executive VP & CFO

Yes. Well, thank you, thanks for the invitation for the -- to be at the meeting here and the opportunity to present at the fireside chat. In the course of the discussion today, we'll be making forward-looking statements. So I'll refer you to the SEC filings that we do from time to time.

So I guess from an Exelixis perspective, we're a commercial-stage oncology company, profitable, cash flow generating. We don't have any debt. We have $850 million of cash and no debt. And we have an asset in cabozantinib, which is currently approved in frontline RCC, second line later RCC, second line later HCC. We also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot